Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Simon Diallo

Showing results (81-90 of 92) with videos related to

Pageof 10
Sort By:
Nature Communications|March 31, 2015
Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killingRozanne Arulanandam, Cory Batenchuk, Oliver Varette, et al.
Frontiers in Immunology|January 30, 2023
CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOXJack T Whelan, Ragunath Singaravelu, Fuan Wang, et al.
Frontiers in Immunology|November 21, 2022
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancerMathieu J F Crupi, Zaid Taha, Thijs J A Janssen, et al.
Nature Medicine|April 21, 2015
Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activityCarolina S Ilkow, Monique Marguerie, Cory Batenchuk, et al.
Nature Communications|August 23, 2024
Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapyZaid Taha, Mathieu Joseph François Crupi, Nouf Alluqmani, et al.
Cancer Cell|July 28, 2015
VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus InfectionRozanne Arulanandam, Cory Batenchuk, Fernando A Angarita, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 8, 2022
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screenZaid Taha, Rozanne Arulanandam, Glib Maznyi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 23, 2021
Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infectionStephen Boulton, Joanna Poutou, Nikolas T Martin, et al.
ACS Infectious Diseases|October 18, 2021
Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of ConcernMadalina Elena Carter-Timofte, Rozanne Arulanandam, Naziia Kurmasheva, et al.
Nature Biomedical Engineering|November 28, 2024
Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic virusesReza Rezaei, Stephen Boulton, Mahsa Ahmadi, et al.
Pageof 10

Showing results (81-90 of 92) with videos related to

Sort By:
Pageof 10
Nature Communications|March 31, 2015
Microtubule disruption synergizes with oncolytic virotherapy by inhibiting interferon translation and potentiating bystander killingRozanne Arulanandam, Cory Batenchuk, Oliver Varette, et al.
Frontiers in Immunology|January 30, 2023
CRISPR-mediated rapid arming of poxvirus vectors enables facile generation of the novel immunotherapeutic STINGPOXJack T Whelan, Ragunath Singaravelu, Fuan Wang, et al.
Frontiers in Immunology|November 21, 2022
Oncolytic virus driven T-cell-based combination immunotherapy platform for colorectal cancerMathieu J F Crupi, Zaid Taha, Thijs J A Janssen, et al.
Nature Medicine|April 21, 2015
Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activityCarolina S Ilkow, Monique Marguerie, Cory Batenchuk, et al.
Nature Communications|August 23, 2024
Complementary dual-virus strategy drives synthetic target and cognate T-cell engager expression for endogenous-antigen agnostic immunotherapyZaid Taha, Mathieu Joseph François Crupi, Nouf Alluqmani, et al.
Cancer Cell|July 28, 2015
VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus InfectionRozanne Arulanandam, Cory Batenchuk, Fernando A Angarita, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|May 8, 2022
Identification of FDA-approved bifonazole as a SARS-CoV-2 blocking agent following a bioreporter drug screenZaid Taha, Rozanne Arulanandam, Glib Maznyi, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|October 23, 2021
Single-dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infectionStephen Boulton, Joanna Poutou, Nikolas T Martin, et al.
ACS Infectious Diseases|October 18, 2021
Antiviral Potential of the Antimicrobial Drug Atovaquone against SARS-CoV-2 and Emerging Variants of ConcernMadalina Elena Carter-Timofte, Rozanne Arulanandam, Naziia Kurmasheva, et al.
Nature Biomedical Engineering|November 28, 2024
Antibiotic-mediated selection of randomly mutagenized and cytokine-expressing oncolytic virusesReza Rezaei, Stephen Boulton, Mahsa Ahmadi, et al.
Pageof 10